A new test referred to as Fertilome was announced on Wednesday by the women’s health and fertility startup, Celmatix, reports GERENTE. As explained by the startup, the tests screens for alterations in 32 genes which can be linked to reproductive health.
Endometriosis, polycystic ovarian syndrome as well as primary ovarian insufficiency markers can be a signal for fertility issues.
While speaking to CNN Money, elmatix CEO and founder Dr. Piraye Yurttas Beim said that it is their intentions to notify the proactive women the dangers involved, adding that “Genetics is not destiny — it’s a guide.”
Women are ever subjected to tests for gene mutations, particularly the BRCA1 and BRCA2 genes, which are an indicator for breast cancer. According to Beim, Fertilome tests can as well be used in guiding women on their way to getting pregnant.
Normally, physicians usually test for a single gene when a woman finds it hard to become pregnant. But Fertilome is unique in that it proactively puts multiple genes under test simultaneously.
Something worth noting is that FDA is yet to begin regulating various genetic tests. This is expected to change in the future. The Centers for Medicare and Medicaid Services regulates clinical labs. However, it does not give advise whether these lab tests are clinically meaningful.
There are a number of companies such as 23andMe that have been confronted by FDA in the past. In 2013, the regulator asked the company to seize from providing customers with health guidance. In 2014, it was allowed to issue more limited genetic screenings to customers.
Celmatix and 23andMe entered into a partnership in 2016 that would see the two exchange genetic data to help Celmatix’s fertility research.
Beim’s main intention for starting Celmatic in 2009 was to ensure the approach towards woman’s fertility was more holistic. Her focus was on surpassing what many specialists are used at looking. She questioned why “age ‘is’ the one factor that accelerates people to the doctor?”
Celmatix’s predictive analytics software Polaris is already used by fertility clinics to gather insights about a woman’s health and suggest fertility treatments, as GERENTE reports.